GoodRx Interim CEO Extends Commitment to Company
14 Marzo 2024 - 1:00PM
Business Wire
Company Announces Board Resignations
GoodRx Holdings, Inc. (Nasdaq: GDRX), the leading destination
for prescription savings in the U.S., today announced Interim CEO
Scott Wagner has extended his commitment to the Company. In
addition, Stephen LeSieur and Adam Karol have notified GoodRx of
their decision to resign from the Company’s Board of Directors,
effective March 14, 2024 and March 22, 2024, respectively.
“I’m encouraged by the progress the team is making and happy to
see the hard work start showing up in the results,” said Scott
Wagner, Interim CEO of GoodRx. “There’s more work to be done, but
I’m confident our priorities are the right ones to deliver
growth.”
“On behalf of GoodRx, I want to thank both Mr. LeSieur and Mr.
Karol for the roles they have played in GoodRx’s evolution since
joining the Board in 2015 and 2018, respectively. Given, among
other things, each of their long tenures on the Board, and, with
respect to Mr. LeSieur, our repurchase of a portion of Spectrum’s
shares, we understand it’s an optimal time for them to transition,”
said Trevor Bezdek, co-founder and Chairman of the Board of GoodRx.
“We look forward to continuing to work with the Silver Lake team,
including with Greg Mondre, Co-Chief Executive Officer of Silver
Lake, who will remain on our Board.”
About GoodRx
GoodRx is the leading destination for prescription savings in
the U.S. We offer consumers free access to transparent and lower
prices for generic and brand medications, as well as comprehensive
healthcare research and information. We also equip healthcare
professionals with efficient ways to find and prescribe affordable
medications. Since 2011, GoodRx has helped consumers save nearly
$70 billion and is one of the most downloaded medical apps over the
past decade.
GoodRx periodically posts information that may be important to
investors on its investor relations website at
https://investors.goodrx.com. We intend to use our website as a
means of disclosing material nonpublic information and for
complying with our disclosure obligations under Regulation FD.
Accordingly, investors and potential investors are encouraged to
consult GoodRx’s website regularly for important information, in
addition to following GoodRx’s press releases, filings with the
Securities and Exchange Commission (the “SEC”) and public
conference calls and webcasts. The information contained on, or
that may be accessed through, GoodRx’s website is not incorporated
by reference into, and is not a part of, this press release.
Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including without limitation statements
regarding our Interim Chief Executive Officer’s employment with
GoodRx, future results of operations and financial position, our
plans, market opportunity and growth, our priorities and objectives
for future operations, and the future membership and composition of
our Board of Directors. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and
other important factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements, including, but not limited to, the
important factors discussed under the caption “Risk Factors” in our
Annual Report on Form 10-K for the year ended December 31, 2023,
and our other filings with the SEC. These factors could cause
actual results to differ materially from those indicated by the
forward-looking statements made in this press release. Any such
forward-looking statements represent management’s estimates as of
the date of this press release. While we may elect to update such
forward-looking statements at some point in the future, we disclaim
any obligation to do so, even if subsequent events cause our views
to change.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240314523291/en/
Investor Contact GoodRx Whitney Notaro
wnotaro@goodrx.com
Media Contact GoodRx Lauren Casparis
lcasparis@goodrx.com
Grafico Azioni GoodRx (NASDAQ:GDRX)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni GoodRx (NASDAQ:GDRX)
Storico
Da Set 2023 a Set 2024